[Asia Economy Reporter Yoo Hyun-seok] Codiem is showing strong performance. It appears that the news of Future Medicine, the second largest shareholder, being designated as a key support candidate among government-supported pharmaceutical and bio companies has had an impact.


As of 2:09 PM on the 7th, Codiem was trading at 356 won, up 5.01% (17 won) compared to the previous trading day.


On the 6th, the government-wide support group for COVID-19 therapeutics and vaccine development announced that it has selected and is managing 14 domestic COVID-19 therapeutic development companies and 7 vaccine development companies as key support candidates. Among them, Future Medicine was selected as a company developing new drugs such as antibody therapeutics and plasma therapeutics using immune proteins, along with Celltrion, Komipharm, Novacell Technology, Eutilex, Enzychem Lifescience, and GC Green Cross.


Future Medicine has been developing therapeutics for MERS coronavirus and SARS coronavirus (SARS-CoV) and has filed patents for synthetic drug candidate substances through joint research with Seoul National University and Leiden University in the Netherlands.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

Professor Jung Nak-shin, who led this research, is an expert in RNA virus therapeutic development based on nucleosides, and Future Medicine is conducting coronavirus therapeutic development centered around Professor Jung.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing